Cutaneous Lupus Erythematosus

A systematic review and meta-analysis presented at ACR Convergence 22 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without systemic lupus erythematosus.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 10, 2022.

“Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.”

"Chronic cutaneous lupus erythematosus is prone to cause substantial disfigurement on visible skin, negatively impacting patients’ mental health and social life."

Although the role of PPIs in the occurrence of both drug-induced systemic lupus erythematosus and drug-induced cutaneous lupus erythematosus has been suggested, it remains poorly characterized.

Despite advancements over the years, cutaneous lupus erythematosus (CLE) continues to represent a high unmet medical need with no cure.

Researchers cite a lack of knowledge on the disease and treatments, which they believe affect the quality of life of patients.

The list of drugs suspected to cause drug-induced lupus erythematosus now includes metoclopramide hydrochloride, levothyroxine sodium, metronidazole hydrochloride and fexofenadine hydrochloride, according to a study published online this month in JAMA Dermatology.

Is it a form of lupus, myositis, or a drug reaction? Check your knowledge of skin eruptions and the associated rheumatologic conditions in this brief photo essay.